Vertex Pharmaceuticals Incorporated (VRTX) is a Healthcare stock trading at $485.58 (as of 2026-07-17), with a market capitalization of $123.24B and a trailing P/E of 28.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Vertex Pharmaceuticals Incorporated develops and commercializes therapies, including cystic fibrosis treatments such as SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, and TRIKAFTA for patients with specified CFTR mutations. The company also advances additional programs in areas including AAT deficiency, kidney diseases, and diabetes, selling its medicines through specialty channels.
Vertex Pharmaceuticals develops and commercializes cystic fibrosis therapies, and makes money by marketing and selling CFTR-targeted medicines such as TRIKAFTA, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to eligible patients based on specific CF mutations.
Vertex's near-term profit model is structurally driven by product sales of CFTR modulators for cystic fibrosis, especially TRIKAFTA/KAFTRIO, since these therapies are marketed to patients with specific CFTR mutations.
| TRIKAFTA/KAFTRIO | $2.6B |
| ALYFTREK | $0.4B |
Business quality (Strong): Strong current earnings power shows up in high operating margin (38.1%), but the commercial engine is concentrated in CF product sales tied to specific mutation eligibility, while pipeline progress remains a key uncertainty.
Valuation: At 25× earnings, VRTX trades 51% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $485.58 |
| Market Cap | $123.24B |
| P/E Ratio | 28.4 |
| EV / EBITDA | 24.0 |
| Price / Book | 6.37 |
| Price / Sales | 10.09 |
| FCF Yield | 3.0% |
| DCF Value (model) | $62.94 |
| DCF Upside vs Price | -87.0% |
| Revenue (TTM) | $12.00B |
| Net Margin | 32.9% |
| Revenue Growth (YoY) | 7.8% |
| EPS Growth (YoY) | 61.1% |
| FCF Growth (YoY) | 66.4% |
| Altman Z-Score | 12.70 (safe) |
| Stock P/E | 28.4 |
| Sector P/E (Healthcare) | 21.4 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | 32.5% |
| vs Industry | 67.4% |
| Top Institutional Holder | Capital World Investors ($11.33B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Reshma Kewalramani |
| Employees | 6,100 |
| Country | US |
| IPO Date | 1991-07-24 |
Data as of 2026-07-17.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.